Plasma KRAS-Mutated Cell-Free DNA Dynamics and Prognostic Associations During the First Chemotherapy Cycle in Pancreatic Ductal Adenocarcinoma
Diagnostics · 15.11.2026 · 16 (22) · 3790
DOI: 10.3390/diagnostics16223790 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 15.11.2026. Verfasst von Mark Jain und 7 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lomonosov Moscow State University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background/Objectives: Within-cycle changes in circulating tumor-derived DNA may provide prognostic information in pancreatic ductal adenocarcinoma (PDAC). This exploratory study investigated KRAS-mutated cell-free DNA (mKRAS cfDNA) dynamics during the first chemotherapy cycle and their associations with disease characteristics, progression, and overall survival.
Methods
A total of 40 patients contributed 151 plasma samples collected at Pre-cycle, Early-cycle, Post-infusion, and Late-cycle time points. Droplet digital PCR targeting KRAS codons 12, 13, and 61 quantified mKRAS cfDNA concentration and mutant allele fraction (MAF). Total cfDNA and CA 19-9 were also evaluated. For the analysis of survival associations, patients were followed for up to 4 years. Results: mKRAS cfDNA was detected in at least one sample from 29 patients (72.5%). Pre-cycle mKRAS cfDNA concentration and MAF were higher in patients with metastatic disease (all p < 0.0001). Both parameters decreased between Pre-cycle and Late-cycle (both p < 0.001), whereas total cfDNA showed no significant overall change. mKRAS cfDNA and MAF weakly correlated with CA 19-9 at most investigated time-points (ρ 0.396–0.523). Late-cycle positivity was associated with shorter subsequent overall survival after adjustment for age and metastatic status (adjusted hazard ratio 5.36; 95% confidence interval: 1.54–18.64; p = 0.0083). Clinical sensitivity analyses yielded directionally consistent estimates; however, the association was attenuated and became statistically inconclusive after adjustment for CA 19-9 dynamics. Pre-cycle positivity and early increases in MAF were associated with shorter survival in unadjusted analyses but did not retain significance after adjustment. No significant associations with progression were identified among 31 evaluable patients.
Conclusions
Late-cycle mKRAS cfDNA detection warrants further evaluation as an on-treatment prognostic marker in PDAC. Larger studies with standardized sampling and external validation are needed to establish its clinical usefulness and added value beyond established assessments.
Förderung
- Lomonosov Moscow State University
Zitieren
APA
Jain, M., Dakhtler, T., Rakhmatullin, T., Atayan, D., Gundobina, M., Gontareva, I., Samokhodskaya, L., & Egorov, V. (2026). Plasma KRAS-Mutated Cell-Free DNA Dynamics and Prognostic Associations During the First Chemotherapy Cycle in Pancreatic Ductal Adenocarcinoma. Diagnostics, 16(22), 3790. https://doi.org/10.3390/diagnostics16223790
Vancouver
Jain M, Dakhtler T, Rakhmatullin T, Atayan D, Gundobina M, Gontareva I, et al. Plasma KRAS-Mutated Cell-Free DNA Dynamics and Prognostic Associations During the First Chemotherapy Cycle in Pancreatic Ductal Adenocarcinoma. Diagnostics. 2026;16(22):3790. doi:10.3390/diagnostics16223790
BibTeX
@article{Jain2026,
author = {Jain, Mark and Dakhtler, Tatiana and Rakhmatullin, Tagir and Atayan, David and Gundobina, Margarita and Gontareva, Iuliia and Samokhodskaya, Larisa and Egorov, Vyacheslav},
title = {Plasma KRAS-Mutated Cell-Free DNA Dynamics and Prognostic Associations During the First Chemotherapy Cycle in Pancreatic Ductal Adenocarcinoma},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3790},
doi = {10.3390/diagnostics16223790}
}
EUVIMED